BY13 是一种 DC50 为 0.031 μM 的 SRC-3 PROTAC 降解剂,通过下调 ERα 水平选择性阻断 ER 信号通路,其选择性高于对雄激素受体 (AR) 的选择性,并通过诱导细胞周期停滞于 G1 期及细胞凋亡 (apoptosis) 有效克服乳腺癌的内分泌耐药性,作用优于 Fulvestrant (MS-S35194),同时显著抑制 LCC2 异种移植小鼠模型中耐药乳腺肿瘤的生长且无明显毒性(粉色:SRC-3 配体 (MS-Y63251);蓝色:Cereblon 配体 (MS-V29738);黑色:连接子 (MS-U13845))。
BY13
产品编号: MS-G40297 分子式: C35H35N9O4 分子量: 645.71
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

BY13 是一种 DC50 为 0.031 μM 的 SRC-3 PROTAC 降解剂,通过下调 ERα 水平选择性阻断 ER 信号通路,其选择性高于对雄激素受体 (AR) 的选择性,并通过诱导细胞周期停滞于 G1 期及细胞凋亡 (apoptosis) 有效克服乳腺癌的内分泌耐药性,作用优于 Fulvestrant (MS-S35194),同时显著抑制 LCC2 异种移植小鼠模型中耐药乳腺肿瘤的生长且无明显毒性(粉色:SRC-3 配体 (MS-Y63251);蓝色:Cereblon 配体 (MS-V29738);黑色:连接子 (MS-U13845))。

生物实验数据

生物活性 BY13 is an SRC-3 PROTAC degrader with a DC50 of 0.031 μM that selectively blocks the ER signaling pathway by downregulating ERα levels, with selectivity over the androgen receptor (AR), and effectively overcomes endocrine resistance in breast cancer by inducing G1 phase cell cycle arrest and apoptosis (apoptosis), outperforming Fulvestrant (MS-S35194), while significantly inhibiting the growth of resistant breast tumors in an LCC2 xenograft mouse model without obvious toxicity (pink: SRC-3 ligand (MS-Y63251); blue: Cereblon ligand (MS-V29738); black: linker (MS-U13845)).
IC50 & Target

ERα

 

SRC-3

0.031 μM (DC50)

体外研究
(In Vitro)

BY13 (0.1-10 μM,24 小时) 剂量依赖性地降低 MCF-7 细胞中的 SRC-3 和 ERα 蛋白水平,分别降解 71% 和 85%。
BY13 (0.01-10 μM,36 小时) 有效抑制野生型、突变型和耐药型乳腺癌细胞的增殖 (对 MCF-7、LCC2 和 MCF-7D538G/Y537S/EGFR 细胞的 IC50 为 0.003-0.35 μM),并以剂量依赖性方式降解突变型细胞中的 SRC-3 和 ERα (尤其是在 MCF-7Y537S 细胞中 (0.1 μM))。
BY13 (0.1-10 μM,3-48 小时) 有效降低 LCC2 细胞中 SRC-3 和 ERα 蛋白水平,其效果优于 Fulvestrant (MS-S35194),并在 36 小时后达到最大降解,且几乎不再随时间增加。
BY13 (0.01-20 μM,36 小时) 显著降低 MCF-7 细胞中 SRC-3 (仅 0.1 μM) 和 ERα (仅 1 μM) 的蛋白水平 (SRC-3 的 DC50 为 0.031 μM),且对 SRC-1 亚型选择性优于 SRC-2。
BY13 (0.01-5 μM,24 小时) 下调了 MCF-7 细胞中 AR 的蛋白水平,但这种作用比 ERα 弱,并且中度抑制 LNCaP 细胞中 AR 过表达 (IC50:1.43 μM)。
BY13 (1 μM,36 小时) 通过泛素蛋白酶体系统 (UPS) 通路显著降低 MCF-7 细胞中 SRC-3 蛋白水平 (在 LCC2 细胞中观察到类似现象)。
BY13 (1 μM,6 小时,40-76℃) 可以进入肿瘤细胞并直接与 SRC-3 结合,显著增强 MCF-7 细胞中 SRC-3 蛋白在高温下的热稳定性。
BY13 (10 μM,6 小时) 诱导 MCF-7 细胞中 SRC-3 和 CRBN 的空间接近,进而促进 SRC-3-BY13-CRBN 三元复合物的形成。
BY13 (0.01-10 μM,36小时) 随着浓度增加,显著增加 LCC2 细胞中 SRC-3 的 mRNA 表达,并有效降低 ERα 的 mRNA 水平。
BY13 (1-20 μM,48小时) 显著诱导乳腺癌细胞凋亡,增强 MCF-7 和 LCC2 细胞的早期和晚期凋亡。
BY13 (5-20 μM,48小时) 剂量依赖性地将 LCC2 细胞阻滞于G1期,且细胞比例明显高于 S 期。
BY13 (0.01-100 μM) 具有足够的代谢稳定性和可接受的安全性,对 CYP3A4 和 hERG 通道的 IC50 分别为 2.73 和 1.1 μM。

Western Blot Analysis

Cell Line: MCF-7 cells, LCC2 cells
Concentration: 0.01, 0.1, 1, 5, 10 μM
Incubation Time: 24 h
Result: Degraded both SRC-3 and ERα protein in MCF-7 cells at 1 μM with 71% and 85% degradation, respectively.
Dose-dependently reduced SRC-3 and ERα protein level in MCF-7 cells without a canonical “hook effect” as well as significantly degrades SRC-3 and ERα in LCC2 cells, superior to Fulvestrant (MS-S35194).
Down-regulated the protein level of AR while this effect is weaker compared to ERα in MCF-7 cells

Western Blot Analysis

Cell Line: MCF-7 cells, LCC2 cells
Concentration: 1 μM
Incubation Time: MCF-7 cells (3, 6, 9, 12, 24, 36 h), LCC2 cells (3, 6, 9, 12, 24, 36, 48 h)
Result: Effectively reduced the SRC-3 protein level after 24h and reached the maximal degradation in MCF-7 cells at 36 h. Significantly reduced the protein level of SRC-3 after only 9 h of treatment, and reached the maximal degradation in LCC2 cells at 36 h with almost no longer increase of degradation.

Western Blot Analysis

Cell Line: MCF-7 cells, LCC2 cells
Concentration: 1 μM after 1 μM of MG-132, Bortezomib, Chloroquine or (BY13-Neg, SI-2 and Pomalidomide) for 2 h
Incubation Time: 36 h
Result: Significantly reduced SRC-3 protein level depending on a ubiquitin proteasome system (UPS) pathway, but this effect was reversed by two proteasome inhibitors (MG-132, Bortezomib and SI-2) not by BY13-Neg in MCF-7 cells (similar symptoms observed in LCC2 cells).

Apoptosis Analysis

Cell Line: MCF-7 cells, LCC2 cells
Concentration: 1, 5, 10, 20 μM
Incubation Time: 48 h
Result: Effectively induced cell apoptosis with enhancement of both early and late apoptosis in MCF-7 cells at increased concentrations (35% maximal early apoptosis rate).
Mainly induced the late apoptosis at 1 μM, but resulted in early apoptosis at 10 μM and induced a strong early apoptotic effect at 20 μM (> 30% early apoptosis rate) in LCC2 cells.
体内研究
(In Vivo)

BY13 (3-10 μM/kg,腹腔注射,每两天一次,共 23 天) 通过靶向 SRC-3 和 ERα 降解,在 LCC2 异种移植小鼠模型中发挥强效的抗内分泌抗性活性,其安全性高,并且改善了内分泌抗性乳腺癌的不良预后。

Animal Model: Female Balb/c nude mice (4 weeks old) were injected subcutaneously into the right lower axilla with LCC2 cells (5 × 106 cells/mouse) to induce LCC2 xenograft mice model.
Dosage: 3, 5 10 μM/kg, Tamoxifen (10 μM/kg) and Fulvestrant (5 μM/kg)
Administration: i.p., once every two days for 23  days after tumors reached approximately 100 mm3, and then collected sample at 36 day1.
Result: Significantly inhibited tumor growth at 3 μM/kg, with superior effect of 54% tumor growth inhibition rate 54% at 5 μM/kg.
Almost completely degraded SRC-3 protein within the tumor tissues at 3 μM/kg, and the protein levels of both SRC-3 and ERα were further decreased at 5 μM/kg.
Had a wide therapeutic window, without effect weight gain of mice model up to 10 μM/kg.
Had a high safety property without observable histopathological changes in the organ tissues of mice model during the administration period at 3 and 5 μM/kg.
Improved the poor prognosis of endocrine-resistant breast cancer with reducement of ki67 level in tumor tissues at 3 and 5 μM/kg.

化学信息

分子量 645.71
分子式 C35H35N9O4

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础